Cas:152356-67-7 3-bromo-5,7,8,9-tetrahydrobenzo[7]annulen-6-one manufacturer & supplier

We serve Chemical Name:3-bromo-5,7,8,9-tetrahydrobenzo[7]annulen-6-one CAS:152356-67-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-bromo-5,7,8,9-tetrahydrobenzo[7]annulen-6-one

Chemical Name:3-bromo-5,7,8,9-tetrahydrobenzo[7]annulen-6-one
CAS.NO:152356-67-7
Synonyms:3-bromo-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-one;3-bromo-5,7,8,9-tetrahydro-benzocyclohepten-6-one
Molecular Formula:C11H11BrO
Molecular Weight:239.10800
HS Code:2914700090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:17.07000
Exact Mass:237.99900
LogP:2.89700

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-bromo-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-bromo-5,7,8,9-tetrahydro-benzocyclohepten-6-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-bromo-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-one Use and application,3-bromo-5,7,8,9-tetrahydro-benzocyclohepten-6-one technical grade,usp/ep/jp grade.


Related News: Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. 1-Diphenylphosphinyl-3-n-butyl-harnstoff manufacturers Expedite biocatalysis development by partnering with an API CDMO 2-{4-[2-amino-3-(4-fluorophenyl)-propionyl]-3-propyl-piperazin-1-yl}-3-(3-fluorophenyl)-N-methyl-propionamide suppliers The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. Pyrido[3,4-d]pyrimidin-4(3H)-one, 2-(1-bromopropyl)-3-(phenylmethyl)- vendor & factory.